Literature DB >> 8407122

The use of tissue plasminogen activator in postvitrectomy cases.

C Koutsandrea1, M Apostolopoulos, P Theodossiadis.   

Abstract

The study concerns 17 eyes which, following vitrectomy, were given an injection of 25 micrograms of tissue plasminogen activator (tPA). Of these 17 cases, ten showed a severe fibrin formation in the anterior chamber, 3 cases showed vitreous hemorrhage (one of them with hyphema), 2 had fibrin formation and cellular proliferation, while in one case tPA was injected at the end of the vitrectomy because of perisilicone proliferation and in one case because of fibrin depositions on the intraocular lens. The tPA was injected into the anterior chamber (10 eyes) or into the vitreous cavity (7 eyes). The follow-up period ranged from 4 to 15 months (mean period 9 1/2 months). Fibrinolysis was noted in the 10 cases with fibrin formation in the anterior chamber. Fibrin dissolution was achieved within 3-4 hours. None of these cases presented a recurrence throughout the follow-up period. Positive results were observed also in the case with perisilicone proliferation. On the contrary in 3 cases with postvitrectomy hemorrhage the hemorrhage persisted unchanged. Also in 2 cases with fibrin formation and cellular proliferation on the anterior and posterior surface of the iris the tPA injection proved ineffective. Both cases developed traction retinal detachment (TRD) due to anterior proliferative vitreoretinopathy (PVR). In the case with fibrin depositions on the intraocular lens the situation remained unchanged. Any complications observed in our case proved to be mild and transitory.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407122     DOI: 10.1007/bf00942782

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  21 in total

1.  Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy.

Authors:  J C Folk; J M Hershey; M B Rivers
Journal:  Arch Ophthalmol       Date:  1991-05

2.  Tissue plasminogen activator for postvitrectomy fibrin formation.

Authors:  G J Jaffe; G W Abrams; G A Williams; D P Han
Journal:  Ophthalmology       Date:  1990-02       Impact factor: 12.079

3.  Rebleeding in experimental traumatic hyphema treated with intraocular tissue plasminogen activator.

Authors:  D F Williams; D P Han; G W Abrams
Journal:  Arch Ophthalmol       Date:  1990-02

4.  The effect of tissue plasminogen activator on retinal bleeding.

Authors:  P Sternberg; H E Aguilar; C Drews; T M Aaberg
Journal:  Arch Ophthalmol       Date:  1990-05

5.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.

Authors:  D O Williams; J Borer; E Braunwald; J H Chesebro; L S Cohen; J Dalen; H T Dodge; C K Francis; G Knatterud; P Ludbrook
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

6.  Use of tissue plasminogen activator in experimental hyphema.

Authors:  F H Lambrou; R W Snyder; G A Williams
Journal:  Arch Ophthalmol       Date:  1987-07

7.  Intraocular tissue plasminogen activator in a rabbit model of traumatic hyphema.

Authors:  G R Howard; J Vukich; R G Fiscella; M D Farber; M F Goldberg
Journal:  Arch Ophthalmol       Date:  1991-02

8.  Tissue plasminogen activator treatment of experimental subretinal hemorrhage.

Authors:  H Lewis; S C Resnick; J G Flannery; B R Straatsma
Journal:  Am J Ophthalmol       Date:  1991-02-15       Impact factor: 5.258

9.  Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage.

Authors:  R N Johnson; K R Olsen; E Hernandez
Journal:  Arch Ophthalmol       Date:  1989-06

10.  Recombinant tissue plasminogen activator to lyse experimentally induced retinal arterial thrombi.

Authors:  A K Vine; P T Maguire; C Martonyi; M C Kincaid
Journal:  Am J Ophthalmol       Date:  1988-03-15       Impact factor: 5.258

View more
  3 in total

1.  Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.

Authors:  A Glacet-Bernard; D Kuhn; A K Vine; H Oubraham; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

Review 3.  Vitreous haemorrhage in elderly patients: management and prevention.

Authors:  Kaykhosrov Manuchehri; Graham Kirkby
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.